The value of SUV in 18F-FDG and 18F-FLT PET imaging for diagnosing pulmonary nodules

目的:探讨18F-氟氏脱氧葡萄糖(18F-FDG)和18F-氟氏胸腺嘧啶(18F-FLT)PET显像诊断肺结块的影响因素,以提高PET/CT对肺结块的诊断价值.方法:选择肺结块患者55例为研究对象,其中28例为肺内孤立结块,其余为2～3个结块,结块大小0.6～11.0 cm.所有患者均行肺部18F-FDG和18F-FLT PET/CT检查.检查结果按不同性别、年龄、结块大小及病理类型进行分组,以各组18F-FDG和18F-FLT显像标准摄取值(SUV)的均数为界定标准.分析SUV与肺结块患者的性别、年龄、结块大小及病理类型等相互关系.结果:55例肺结块患者,不同性别、年龄、结块大小患者的18F-FDG和18F-FLT显像SUV差异均无统计学意义(P>0.05),不同病理类型患者的18F-FDG显像SUV差异无统计学意义(P>0.05),而不同病理类型患者的18F-FLT显像SUV差异有统计学意义(P<0.05).结论:肺结块患者结块的病理类型是影响18F-FLT显像SUV的重要因素,18F-FLT PET/CT显像SUV鉴别诊断肺结块良恶性具有重要的价值和意义.     

18F-FDG和18F-FLT PET/CT在肺部良恶性肿瘤鉴别诊断中的价值

目的:分析18F-FDG(18F-脱氧葡萄糖)和18F-FLT(18F-胸腺嘧啶)两种显像剂的PET/CT检查在肺部肿瘤中的不同影像学表现,提高PET/CT在肺部良恶性肿瘤鉴别诊断中价值,从而为临床治疗方案的选择提供可靠依据。方法:收集肺肿瘤患者55例为研究对象,其中男性33例,女性22例,年龄17～82岁,28例为肺内孤立肿块,其余为2～3个肿块,肿块大小0.6～11.0cm,所有患者均行肺部18 F-FDG和18 F-FLT PET/CT检查,分析18 F-FDG和18 F-FLT标准摄取值(SUV)与肺肿瘤患者的年龄、肿块大小及病理类型等相互关系和统计学意义。结果:18 F-FDG和18 F-FLT PET/CT的SUV与肺肿瘤患者的年龄、肿块大小均无统计学差异(P>0.05),18 F-FDG PET/CT的SUV与患者的病理类型亦无统计学差异(P>0.05),而18F-FLT PET/CT的SUV与患者的病理类型有统计学差异(P<0.05)。结论:肺肿瘤患者的肿块病理类型是影响18F-FLT PET/CT的SUV的重要因素,18F-FLT PET/CT的SUV在肺部良恶性肿瘤鉴别诊断中具有重要的价值。     

^18F-FDG和^18F—FLTPET／CT诊断肺结节影响因素的多中心临床研究

目的:探讨18F-FDG和18F-FLT PET/CT诊断肺结节的影响因素,以提高PET/CT对肺结节的诊断价值.材料和方法:选择肺结节患者55例为研究对象,其中男性33例,女性22例,年龄17～82岁,28例为肺内孤立结节,其余为2～3个结节,结节大小0.6～11.0cm,所有患者均行肺部18F-FDG和18F-FLT PET/CT检查,分析18F-FDG和18F-FLT标准摄取值(SUV)与肺结节患者的性别、年龄、结节大小及病理类型等相互关系和意义.结果:55例肺结节患者,18F-FDG和18F-FLT标准摄取值与患者的性别、年龄、结节大小等均无统计学差异(P>0.05),18F-FDG标准摄取值与患者的病理类型亦无统计学差异(P>0.05),而18F-FLT标准摄取值与患者的病理类型有统计学差异(P<0.05).结论:肺结节患者结节的病理类型是影响18F-FLT标准摄取值的重要因素.18F-FLT PET/CT鉴别诊断肺结节良恶性具有重要的价值和意义.     

18F-FDG和11C-choline PET/CT诊断前列腺良恶性病变的影响因素研究

目的:探讨18F-FDG(18F-脱氧葡萄糖)和11 C-choline(11 C-胆碱)PET/CT显像诊断前列腺良恶性病变的影响因素,以提高PET/CT对前列腺病变的诊断价值。方法:选择可疑前列腺病变患者55例为研究对象,年龄57～82岁,28例为前列腺癌,转移程度不一;其余为前列腺良性病变。所有患者均行全身18 F-FDG和11 C-choline PET/CT检查,分析18 F-FDG和11 C-choline标准摄取值(SUV)与前列病变患者的年龄及病理类型的相互关系和意义。结果:55例前列腺病变患者,18F-FDG和11 C-choline标准摄取值与患者的年龄无统计学差异(P>0.05),18 F-FDG标准摄取值与患者的病理类型亦无统计学差异(P>0.05),而11 C-choline标准摄取值与患者的病理类型有统计学差异(P<0.05)。结论:前列腺病变患者的病理类型是影响11 C-choline标准摄取值的重要因素,11 C-choline PET/CT鉴别诊断前列腺良恶性病变具有重要的价值和意义。     

18F-FDG与18F-FLT PET/CT延迟显像对肺结节诊断效能的评价

目的 通过对多中心、前瞻性研究中接受了18F-脱氧葡萄糖(FDG)与18F-脱氧胸腺嘧啶核苷(FLT)延迟显像病例的分析,探讨18F-FDG与18F-FLT延迟显像对肺结节诊断的效能.方法 6个PET/CT中心,从2006年1月至2007年6月,按照统一标准,采用同机型、同一扫描条件,开展了肺结节样病变18F-FLT和18F-FDG PET/CT显像的多中心临床研究.在经确诊的55例病例中,25例患者进行了18F-FLT显像和延迟显像,34例患者进行了18F-FDG延迟显像.按常规计算延迟显像时病灶最大标准摄取值(SUVmax)及与早期显像时SUVmax相比的变化率(△SUVmax).对照临床确诊结果分析其诊断效能.采用SPSS11.0软件进行统计学处理.结果 18F-FDG延迟显像患者中,6例肺癌中5例、12例结核中9例、16例炎症或其他良性结节中9例的SUVmax较早期相升高.18F-FLT延迟显像组中,7例肺癌中3例、8例结核中3例和10例其他良性病灶中2例的SUVmax上升.经分组统计分析,不同疾病组间18F-FDG延迟显像SUVmax和△SUVmax差异无统计学意义;18F-FLT延迟显像SUVmax和△SUVmax组间差异也无统计学意义.无论18F-FDG还是18F-FLT,延迟显像的诊断效能均不如早期相.无论早期还是延迟显像,单独18F-FDG或18F-FLT显像的诊断效能均不如二者联合应用.结论 18F-FDG和18F-FLT延迟显像的SUVmax变化规律性不强,不宜单独应用于肺结节的鉴别诊断.     

18F-FLT PET/CT与18F-FDG PET/CT在鼻咽癌诊断和分期中的应用比较

目的 通过与18F-FDG PET/CT显像对比,探讨18 F-FLT PET/CT检测鼻咽癌原发灶和颈部淋巴结转移灶的可行性.方法 12例初治且经病理确诊的鼻咽癌患者(年龄22～62岁)自愿进入该前瞻性临床研究.每位患者先行18F-FDG PET/CT检查,次日行18F-FLF PET/CT检查.至少有2位核医学科和放射科医师阅片,比较18F-FDG PET/CT和18F-FLT PET/CT图像,采用ROI技术计算鼻咽肿瘤、颈部淋巴结转移灶、正常组织对18F-FDG、18F-FLT的SUVmax、SUVmean和MTV.采用非参数Wilcoxon秩和检验比较组间摄取和MTV差异.结果 12例鼻咽癌患者病灶均明显摄取18F-FLT.18F-FLT PET/CT和18F-FDG PET/CT均可准确诊断该组病例,二者对原发灶和淋巴结转移灶的检测结果无明显差别.鼻咽癌病灶的18F-FDG和18F-FLT SUVmax分别为10.7±5.8和6.0±2.4,SUVmean分别为5.8±3.0和3.6±1.5;SUVmax和SUVmean组间差异均有统计学意义(Z=-2.589和-2.353,P均＜0.05),而 MTV在18F-FDG和8F-FLT PET/CT 2种显像方法之问的差异无统计学意义(15.9±9.2和18.1±11.1;Z=-0.786,P＞0.05).6例有颈部淋巴结转移灶患者的SUVmax、SUVmean和MTV在2种显像方法间差异均无统计学意义(8.5±6.2比6.4±2.5、5.3±4.2比3.8±1.4、6.5 ±4.8比6.0±4.4;Z=-0.734、-0.734和-0.674,P均＞0.05).18F-FLT在颞叶摄取(SUVmax 0.7±0.3)明显低于18F-FDG(SUVmax 8.3±2.7;Z=-3.062,P＜0.01),其对于原发灶颅内浸润显示较18F-FDG更清晰.结论 18F-FLT PET/CT在鼻咽癌原发灶和淋巴结转移灶的诊断效能与18F-FDG PET/CT相当,对于显示原发灶的颅底附近侵犯更有利,其临床应用值得进一步研究.     

18F-FLT与18F-FDG PET/CT不同判断方法鉴别肺良恶性肿瘤诊断效能的比较

目的 通过分析多中心临床研究病例,比较18F-脱氧胸腺嘧啶核苷(FIT)、18F-脱氧葡萄糖(FDG)PET/CT显像诊断肺恶性肿瘤的效能.方法 通过随机、盲法、前瞻性的多中心研究,获得以病理检查或临床随访结果确定诊断的55例肺结节患者,均同时行18F-FDG和18F-FLT PET/CT检查.应用受试者工作特征(ROC)曲线分析方法,分别计算病灶最大标准摄取值(SUVmax)、视觉评分、集体盲法阅片等方法的曲线下面积,比较不同检查方法、不同诊断方法的诊断效能.结果 目测经病理或随访检查确诊的16例肺癌、16例肺结核、23例肺炎或其他类型疾病患者,18F-FDG和18F-FLT SUVmax、视觉评分法、集体阅片法曲线下面积分别为0.780±0.065,0.768±0.063,0.803±0.068和0.828±0.058,0.709±0.082,0.763±0.072.通过约登指数选择18F-FDG SUVmax≥6.0,18F-FLT SUVmax≥2.4为良恶性诊断阈值,18F-FDG和18F-FLT单独SUVmax法和盲法集体阅片对肺恶性肿瘤诊断的灵敏度、特异性和准确性分别为75.0%(12/16)、64.1%(25/39)、67.3%(37/55),81.3%(13/16)、82.1%(32/39)、81.8%(45/55)和81.3%(13/16)、87.2%(34/39)、85.5%(47/55).结论 18F-FDG、18F-FLT单独诊断肺恶性肿瘤的效能均为中等;18F-FLT SUVmax法优于18F-FDG;18F-FDG和18F-FLT图像结合判读可获得最佳诊断效能.     

18F-FLT联合18F-FDG PET/CT显像对纵隔淋巴结良恶性的诊断价值

目的 评价18F-FLT联合18F-FDG PET/CT显像对肺部恶性肿瘤患者纵隔淋巴结良恶性的诊断价值.方法 回顾性分析2009年4月至2011年10月全国11个PET/CT中心18F-FLT与18 F-FDG PET/CT显像的患者资料,选择行肺部恶性肿瘤切除和纵隔淋巴结清扫、获得病理检查结果的患者共41例,其中男28例,女13例,年龄(56.1 ±12.2)岁.对18F-FLT与18F-FDG PET/CT淋巴结的显像结果分别进行视觉分析和半定量分析,采用,检验比较各方法的诊断效能.结果 (1)41例患者手术共检出533枚淋巴结,经病理检查证实恶性192枚,良性341枚(炎性增生淋巴结或正常淋巴结);(2)以18 F-FDG SUV≥2.5和18F-FLT SUV≥2.0为诊断恶性淋巴结的阈值,18F-FDG和18F-FLTPET/CT对纵隔淋巴结良恶性诊断的灵敏度、特异性、准确性、阳性预测值及阴性预测值分别为91.67％ (176/192)、80.94％ (276/341)、84.80％(452/533)、73.03％(176/241)、94.52％(276/292)和81.25％ (156/192)、92.96％(317/341)、88.74％ (473/533)、86.67％ (156/180)、89.80％ (317/353),两者灵敏度、特异性及阳性预测值差异均有统计学意义(x2=8.897、21.722和11.495,均P＜0.05),准确性和阴性预测值差异均无统计学意义(x2=3.604和3.712,均P＞0.05);18F-FDG联合18 F-FLT诊断纵隔淋巴结的灵敏度、特异性、准确性、阳性预测值及阴性预测值则分别提高至93.75％(180/192)、94.43％ (322/341)、94.18％ (502/533)、90.45％ (180/199)、96.41％(322/334).结论 18F-FDG诊断纵隔淋巴结良恶性的灵敏度高于18F-FLT,但特异性及阳性预测值明显低于FLT,两者联合诊断可明显提高诊断准确性.     

18F-FDG和18F-FLT PET/CT不同诊断方法在肺部单发结节中的临床价值分析

目的：探讨18F-FDG和18F-胸腺嘧啶核苷（FLT）PET/CT不同的诊断方法对肺部单发结节的诊断价值。方法对40例发现肺部单发结节的患者行18F-FDG和18F-FLT PET/CT显像,所有病例均经病理或密切随访确诊,应用受试者工作特征（ROC）曲线比较18F-FDG SUVmax、18F-FLT SUVmax、18F-FLT SUVmax/同层面椎体SUVmax对肺部恶性肿瘤的诊断价值;18F-FDG和18F-FLT PET/CT两种显像结果均行视觉分析和半定量分析,比较不同诊断方法的诊断效能。结果18F-FDG SUVmax、18F-FLT SUVmax及18F-FLT SUVmax/同层面椎体SUVmaxROC曲线下面积分别为0.687、0.821和0.817。以18F-FDG SUVmax>2.5、18F-FLT SUVmax>2.0为恶性诊断标准、18F-FDG PET/CT视觉分析评分法、18F-FLT PET/CT视觉分析评分法4种方法诊断肺癌的灵敏度、特异度和准确率分别为88.2%、73.9%和80.0%;58.8%、82.6%和72.5%;94.1%、91.3%和92.5%;88.2%、65.2%和75.0%。结论18F-FLT SUVmax及18F-FLT SUVmax/同层面椎体SUVmax单独诊断肺部恶性肿瘤的价值较18F-FDG SUVmax高,且前两者可替换使用。18F-FDG PET/CT视觉评分法在肺部单发结节良恶性的诊断中效能最佳。     

18F-FLT联合18F-FDG PET/CT显像对胃癌原发灶及区域淋巴结转移的诊断价值

目的 评价18 F-FLT联合18F-FDG PET/CT显像对胃癌原发灶及区域淋巴结转移的诊断价值.方法 回顾性分析2011年3月至2013年4月间37例经活组织检查证实的胃癌患者临床资料.所有患者术前均行18F-FLT和18F-FDG双显像剂PET/CT检查,对显像结果分别进行视觉分析和半定量分析.应用SPSS 13.0软件分别对不同病理类型原发灶的SUVmax进行两样本t检验,对2种显像方法诊断效能的比较行x2检验.结果 18F-FLT和18F-FDG PET/CT诊断胃癌原发灶的灵敏度分别为89.2％ (33/37)和91.9％ (34/37),差异无统计学意义(x2=0.158,P＞0.05).弥漫型胃癌的18F-FLTSUVmax为6.89±1.38,与肠型胃癌的3.79±2.45差异有统计学意义(t=4.533,P＜0.05);而两者的18F-FDG SUVmax差异无统计学意义(7.13±1.97与6.36±2.32,t=1.066,P＞0.05).18 F-FLT和18 F-FDGPET/CT对胃癌区域淋巴结转移诊断的灵敏度、特异性、准确性分别为64.8％ (35/54)、97.6％(246/252)、91.8％(281/306)和88.9％ (48/54)、82.9％ (209/252)、84.0％ (257/306),差异均有统计学意义(x2=8.796、30.948、8.854,均P＜0.05);两者联合,灵敏度、特异性、准确性分别提高至92.6％(50/54)、98.8％ (249/252)、97.7％ (299/306).结论 18F-FLT是18F-FDG摄取少或不摄取的弥漫型胃癌的补充显像剂;对于胃癌转移淋巴结,18F-FLT比18F-FDG有更高的特异性和准确性,但灵敏度较低,两者联合可提高诊断准确性.     

18F-FDG PET/CT联合肺动脉灌注成像指数在单发肺结节中的应用价值

目的探讨18F-FDG PET/CT联合320容积CT双入口灌注成像(DI-CTP)肺动脉灌注指数(PPI)对单发性肺结节的鉴别诊断价值。方法搜集经病理证实40例单发性肺结节患者的18F-FDG PET/CT及320排CT灌注成像影像资料(恶性结节24例、良性结节16例),PET/CT以结节18F-FDG摄取值SUV≥2.5为诊断恶性结节阈值,18F-FDG PET/CT联合PPI则在SUV≥2.5诊断阈值的基础上综合PPI<50%判定,并分析SUV与PP均值在良恶性结节间差异性及相关性。结果PET/CT联合PPI正确诊断38例,其中恶性结节22例、良性结节16例,误诊2例。18F-FDG PET/CT联合PPI诊断肺单发结节的敏感性91.6%,特异性100%,准确性95.0%;18F-PDG摄取值SUV在良、恶性结间差异无统计学意义(t=1.66,P>0.05),而PPI均值在良、恶性结节间差异有统计学意义(t=-3.14,P<0.01);SUV与PPI间相关性无统计学意义(r=0.20,P>0.05)。结论18F-FDG PET/CT联合PPI可以提高诊断肺单发肺结节敏感性、特异性和准确性,减少误诊率。     

Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.

Recently, the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine (FLT) was suggested for imaging tumoral proliferation. In this prospective study, we examined whether (18)F-FLT better determines proliferative activity in newly diagnosed lung nodules than does (18)F-FDG. METHODS: Twenty-six patients with pulmonary nodules on chest CT were examined with PET and the tracers (18)F-FDG and (18)F-FLT. Tumoral uptake was determined by calculation of standardized uptake value (SUV). Within 2 wk, patients underwent resective surgery or had core biopsy. Proliferative activity was estimated by counting nuclei stained with the Ki-67-specific monoclonal antibody MIB-1 per total number of nuclei in representative tissue specimens. The correlation between the percentage of proliferating cells and the SUVs for (18)F-FLT and (18)F-FDG was determined using linear regression analysis. RESULTS: Eighteen patients had malignant tumors (13 with non-small cell lung cancer [NSCLC], 1 with small cell lung cancer, and 4 with pulmonary metastases from extrapulmonary tumors); 8 had benign lesions. In all visible lesions, mean (18)F-FDG uptake was 4.1 (median, 4.4; SD, 3.0; range, 1.0-10.6), and mean (18)F-FLT uptake was 1.8 (median, 1.2; SD, 2.0; range, 0.8-6.4). Statistical analysis revealed a significantly higher uptake of (18)F-FDG than of (18)F-FLT (Mann-Whitney U test, P < 0.05). (18)F-FLT SUV correlated better with proliferation index (P < 0.0001; r = 0.92) than did (18)F-FDG SUV (P < 0.001; r = 0.59). With the exception of 1 carcinoma in situ, all malignant tumors showed increased (18)F-FDG PET uptake. (18)F-FLT PET was false-negative in the carcinoma in situ, in another NSCLC with a low proliferation index, and in a patient with lung metastases from colorectal cancer. Increased (18)F-FLT uptake was related exclusively to malignant tumors. By contrast, (18)F-FDG PET was false-positive in 4 of 8 patients with benign lesions. CONCLUSION: (18)F-FLT uptake correlates better with proliferation of lung tumors than does uptake of (18)F-FDG and might be more useful as a selective biomarker for tumor proliferation.     

Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.

18F-FDG PET has gained acceptance for staging of esophageal cancer. However, FDG is not tumor specific and false-positive results may occur by accumulation of FDG in benign tissue. The tracer 18F-fluoro-3'-deoxy-3'-L-fluorothymidine (18F-FLT) might not have these drawbacks. The aim of this study was to investigate the feasibility of 18F-FLT PET for the detection and staging of esophageal cancer and to compare 18F-FLT PET with 18F-FDG PET. Furthermore, the correlation between 18F-FLT and 18F-FDG uptake and proliferation of the tumor was investigated. METHODS: Ten patients with biopsy-proven cancer of the esophagus or gastroesophageal junction were staged with CT, endoscopic ultrasonography, and ultrasound of the neck. In addition, all patients underwent a whole-body 18F-FLT PET and 18F-FDG PET. Standardized uptake values were compared with proliferation expressed by Ki-67 positivity. RESULTS: 18F-FDG PET was able to detect all esophageal cancers, whereas 18F-FLT PET visualized the tumor in 8 of 10 patients. Both 18F-FDG PET and 18F-FLT PET detected lymph node metastases in 2 of 8 patients. 18F-FDG PET detected 1 cervical lymph node that was missed on 18F-FLT PET, whereas 18F-FDG PET showed uptake in benign lesions in 2 patients. The uptake of 18F-FDG (median standardized uptake value [SUV(mean)], 6.0) was significantly higher than 18F-FLT (median SUV(mean), 3.4). Neither 18F-FDG maximum SUV (SUV(max)) nor 18F-FLT SUV(max) correlated with Ki-67 expression in the linear regression analysis. CONCLUSION: In this study, uptake of 18F-FDG in esophageal cancer is significantly higher compared with 18F-FLT uptake. 18F-FLT scans show more false-negative findings and fewer false-positive findings than do 18F-FDG scans. Uptake of 18F-FDG or 18F-FLT did not correlate with proliferation.     

大规模人群FDG PET/CT意外发现甲状腺高代谢结节的回顾性分析

目的 对大规模人群中18F-FDG PET/CT意外发现的甲状腺高代谢结节的发病率和良恶性进行回顾性分析.方法 回顾2007年8月至2010年3月间无甲状腺癌病史或甲状腺手术史行PET/CT检查者共计8463例,其中145例意外发现甲状腺高代谢结节,经病理检查和随访明确结节良恶性68例(恶性37例,良性31例).患者中男21例,女47例,年龄21 ～76(53.66±10.85)岁.根据结节的良恶性,进行单因素和多因素分析,单因素分析采用t检验、x2检验或Fisher确切概率法,多因素分析采用二分法logistic回归.分别以SUVmax和logistic回归模型绘制ROC曲线,比较两者AUC.结果 甲状腺高代谢结节的发病率为1.71％( 145/8463),恶性百分率为54.41％( 37/68).良性和恶性结节的SUVmax分别为5.13±4.02和7.61±4.78,差异有统计学意义(t=2.235,P=0.029).Logistic回归分析结果显示有统计学意义的自变量包括SUVmax、有无钙化、是否多发、结节大小和患者年龄.Logistic回归模型的AUC( AUCL)为0.878±0.043 (95％ CI:0.793 ～0.962,P＜0.05),SUVmax的AUC(AUCs)为0.694±0.067(95％ CI:0.562～0.825,P＜0.05),两者差异有统计学意义(P＜0.05).结论 甲状腺高代谢结节有较高的恶性百分率,SUVmax对此类结节良恶性鉴别的意义有限;综合结节的PET/CT影像特征,logistic回归模型可以提高诊断准确性.     

Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?

The objective of this study was to compare 18F-3'-fluoro-3'-deoxy-L-thymidine (FLT) PET with clinical TNM staging, including that by 18F-FDG PET, in patients with non-small cell lung cancer (NSCLC). METHODS: Patients with NSCLC underwent whole-body 18F-FDG PET and whole-body 18F-FLT PET, using a median of 360 MBq of 18F-FDG (range, 160-500 MBq) and a median of 210 MBq of 18F-FLT (range, 130-420 MBq). 18F-FDG PET was performed 90 min after 18F-FDG injection, and 18F-FLT PET was performed 60 min after 18F-FLT injection. Two viewers independently categorized the localization and intensity of tracer uptake for all lesions. All 18F-FDG PET and 18F-FLT PET lesions were compared. Staging with 18F-FLT PET was compared with clinical TNM staging based on the findings of history, physical examination, bronchoscopy, CT, and 18F-FDG PET. From 8 patients, standardized uptake values (SUVs) were calculated. Maximal SUV and mean SUV were calculated. RESULTS: Sixteen patients with stage IB-IV NSCLC and 1 patient with strong suspicion of NSCLC were investigated. Sensitivity on a lesion-by-lesion basis was 80% for the 8 patients who received treatment before 18F-FLT PET and 27% for the 9 patients who did not receive pretreatment, using 18F-FDG PET as the reference standard. Compared with clinical TNM staging, staging by 18F-FLT PET was correct for 8 of 17 patients: 5 of 9 patients in the group with previous therapy and 3 of 8 patients in the group without previous therapy. The maximal SUV of 18F-FLT PET, at a median of 2.7 and range of 0.8-4.5, was significantly lower than that of 18F-FDG PET, which had a median of 8.0 and range of 3.7-18.8 (n = 8; P = 0.012). The mean SUV of 18F-FLT PET, at a median of 2.7 and range of 1.4-3.3, was significantly lower than that of 18F-FDG PET, which had a median of 6.2 and range of 2.8-13.9 (n = 6; P = 0.027). CONCLUSION: 18F-FLT PET is not useful for staging and restaging NSCLC.     

^18F-FDGPET／CT影像特征对甲状腺结节的诊断效能

目的研究甲状腺结节^18F-FDGPET／CT影像特征对甲状腺结节良恶性的鉴别诊断效能。方法回顾性研究68例[男24例,女44例,平均年龄（52．8±10．58）岁]2006年1月至2012年12月间经PET／CT检查发现甲状腺结节且有术后病理结果的患者,分析其PET／CT图像特征并获得特征参数,包括结节边界清晰度、密度均匀性、钙化情况、包膜情况、平均CT值、结节大小及SUVmax。以术后病理结果为“金标准”,采用Mann-Whitney u检验、x^2检验及ROC曲线对各参数的诊断效能进行统计分析。结果68例患者中,病理结果显示恶性18例,良性50例。结节密度是否均匀、有无钙化灶、有无包膜对于甲状腺结节良恶性鉴别均无统计学意义（x^2=0．21、0．01、0．43,均P〉0．05）,结节平均CT值及结节大小亦无鉴别意义（均AUC〈0．5）。结节边界是否清晰对良恶性结节鉴别有统计学意义（x^2=8．06,P〈0．05）,其诊断灵敏度、特异性及准确性分别为55．6％（10／18）、80．0％（40／50）和73．5％（50／68）。良性结节SUVmax为3．16±1．84,恶性结节SUVmax为8．53±7．09,差异有统计学意义（u=-4．281,P〈0．01）。以SUVmax为评价指标,其ROC的AUC为0．841（95％CI：0．726—0．955）,最大约登指数（0．562）对应SUVmax为4．25,其诊断灵敏度、特异性及准确性分别为72．2％（13／18）、84．0％（42／50）和80．9％（55／68）。结论可依据^18F—FDGPET／CTSUVmax对甲状腺结节良恶性进行判断,但同机CT影像特征价值有限。     

孤立性肺病变18F-FDG PET/CT显像诊断价值及误诊原因分析

目的 探讨18F-FDG PET/CT显像对孤立性肺病变的诊断价值及误诊原因.方法 回顾分析32例孤立性肺部病变患者18F-FDG PET/CT显像结果.将PET/CT结果与病理检查结果进行对比,评价18F-FDG PET/CT显像在孤立性肺部病变诊断中的价值,并分析其误诊原因.应用SPSS 16.0软件行统计学分析,SUVmax及SUVmax变化率(△SUVmax)与病灶直径大小关系采用Pearson相关分析.结果 32例孤立性肺部病变中,恶性病变22例,良性病变10例.18F-FDG PET/CT对68.75％( 22/32)患者进行了准确定性诊断.18F-FDG PET/CT显像假阴性5例,假阳性5例.22例肺部恶性病变中,6例恶性病变早期SUVmax ＜2.5,5例恶性病变△SUVmax＜15％.10例肺部良性病变中,2例良性病变早期SUVmax≥2.5,4例良性病变△SUVmax≥15％.良恶性病变SUVmax及△SUVmax有交叉.32例肺部病变中,孤立性肺部病变最大直径≤3 cm共26例,最大直径＞3 cm共6例,平均(1.98±1.08) cm.SUV max与病变直径大小呈正相关(r=0.690,P＜0.01),△SUVmax与病灶直径大小无相关性(r=-0.081,P＞0.05).结论 18F-FDG PET/CT在肺部孤立性病变定性诊断中有重要临床价值,但单纯依靠SUV max存在不足,应将PET与CT综合分析.     

18F-FDG PET显像在胰腺恶性病变鉴别诊断及转移灶探查中的应用价值

目的研究18F-FDGPET显像在胰腺恶性肿瘤诊断与鉴别诊断中的应用价值。方法 40例临床疑为胰腺恶性病变的患者均行18F-FDGPET显像,对显像结果进行目测法及SUV值半定量分析,并结合CT,MRI等影像学检查进行综合诊断,最后诊断根据手术病理或经4个月以上随访证实。结果如果以SUV为2.5作为鉴别诊断胰腺病灶良恶性的阈值,24例证实为胰腺癌患者中18F-FDGPET显像正确诊断22例,16例胰腺良性病变患者18F-FDGPET检出13例,其灵敏度、特异度及准确性分别为91.7%（22/24）,81.3%（13/16）及87.5%（35/40）;而结合CT,MRI等其他检查结果进行综合诊断,其诊断灵敏度、特异度及准确性分别为91.7%（22/24）、87.5%（14/16）及90%（36/40）。恶性病变的SUV平均值为4.6±2.6,良性病变的SUV平均值为2.3±1.5,良恶性病变间SUV平均值差异有统计学意义（P〈0.01）。在转移灶的检出中,18F-FDGPET显像发现了全部38处转移灶,并发现6处CT,MRI未能发现的远处转移病灶,排除了1例CT认为是胰周转移性淋巴结肿大的病例。结论 18F-FDGPET对鉴别诊断胰腺良恶性肿瘤的灵敏度、特异性较高,尤其在远处转移灶的探查中有较高应用价值。